Cannabinoid formulation benefits opioid-refractory pain

June 13, 2012
Cannabinoid formulation benefits opioid-Refractory pain
A novel cannabinoid formulation, nabiximols, is safe and effective for patients with advanced cancer and opioid-refractory pain, especially at a low-dose, according to a study published in the May issue of The Journal of Pain.

(HealthDay) -- A novel cannabinoid formulation, nabiximols, is safe and effective for patients with advanced cancer and opioid-refractory pain, especially at a low-dose, according to a study published in the May issue of The Journal of Pain.

Russell K. Portenoy, M.D., of the Beth Israel Medical Center in , and associates conducted a randomized, double-blind, placebo-controlled, graded-dose study of 263 patients with advanced and opioid-refractory pain. Participants were randomly allocated to receive low-, medium-, or high-dose nabiximols or placebo. During five-weeks of treatment, average pain, worst pain, and sleep were measured daily; and mood were also assessed.

The researchers found that, compared with placebo, the 30 percent responder rate primary analysis was not significant for nabiximols (P = 0.59). In a secondary continuous responder analysis of average daily pain, a significantly higher proportion of patients reported analgesia in the nabiximols group than placebo (P = 0.035), specifically for low-dose and medium-dose nabiximols (P = 0.008 and 0.039, respectively). Results were similar for mean average pain, mean worst pain, and mean sleep disruption in the low-dose group (P = 0.006, 0.011, and 0.003, respectively). There were no significant group differences seen in other . Dose-related adverse events were seen, with only the high-dose group comparing unfavorably with placebo.

"Based on the results of this dose-ranging study, nabiximols in a manageable dose range may prove to offer benefits to a very ill population with refractory pain," the authors write. "Confirmatory studies are strongly warranted."

The study was funded by GW Pharmaceuticals, which produces nabiximols, and Otsuka.

Explore further: Stem cell injections may offer hope to patients with no other options

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Low-dose CT noninferior for diagnosing appendicitis

April 26, 2012

(HealthDay) -- For young adults with suspected appendicitis, low-dose computed tomography (CT) is noninferior to standard-dose CT with respect to negative appendectomy rates, according to a study published in the April 26 ...

Recommended for you

Researchers make link between genetics, aging

February 3, 2016

Scientists at the University of Georgia have shown that a hormone instrumental in the aging process is under genetic control, introducing a new pathway by which genetics regulates aging and disease.

Study uncovers how electromagnetic fields can amplify pain

February 3, 2016

For years, retired Maj. David Underwood has noticed that whenever he drove under power lines and around other electromagnetic fields, he would feel a buzz in what remained of his arm. When traveling by car through Texas' ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.